Scarica l'app Stockscreener
10.65
0.00%
0.00
Dopo l'orario di chiusura:
10.75
0.10
+0.94%
Kura Oncology Inc Borsa (KURA) Ultime notizie
Kura Oncology, Inc. (KURA) stock price, news, quote and history - Yahoo Finance Australia
JPMorgan initiates Kura Oncology stock with overweight rating By Investing.com - Investing.com Canada
Kura Oncology, Inc. : JP Morgan Initiates Cov - Moomoo
Kura Oncology, Inc. (KURA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 4 Kura Oncology Inc For: 29 September By Investing.com - Investing.com Nigeria
Kura Oncology SVP sells $48,360 of stock By Investing.com - Investing.com Australia
Kura Oncology chief legal officer sells $88,618 in shares By Investing.com - Investing.com South Africa
Kura Oncology CCO Brian Powl sells over $345k in company stock - Investing.com Australia
Kura Oncology chief legal officer sells $88,618 in shares - Investing.com
Kura Oncology COO Kathleen Ford sells $111,930 in company stock - Investing.com
Kura Oncology CMO Mollie Leoni reports $440,236 stock sales - Investing.com
Kura Oncology CMO Mollie Leoni reports $440,236 stock sales By Investing.com - Investing.com South Africa
A tax-related sale followed stock vesting: Kura Oncology (KURA) executive sold 4,607 shares. - Stock Titan
One sale covered taxes; two followed a trading plan. Kura Oncology (KURA) executive sold 32,450 shares. - Stock Titan
Return on equity % of Kura Oncology, Inc. – HAN:KUR - TradingView
Kura Oncology, Inc. Revenue Breakdown – HAN:KUR - TradingView
ETFs Investing in Kura Oncology, Inc. Stocks - TradingView
Kura Oncology, Inc. Earnings and Revenue – HAN:KUR - TradingView
After three earlier sales, a Kura Oncology (KURA) officer proposes another share sale - Stock Titan
After selling 12,448 shares, a Kura Oncology (KURA) officer proposes selling 28,802 more. - Stock Titan
Caspian Therapeutics, Inc. And Kura Oncology, Inc. Unveil KO-7246 At EASD As A Potential Best-In-Class Menin Inhibitor For Diabetes - marketscreener.com
Caspian Therapeutics and Kura Oncology Report Preclinical Regenerative Beta-Cell Data for KO-7246 in Diabetes Models - Quiver Quantitative
Form 144 KURA ONCOLOGY For: 28 September By Investing.com - Investing.com Nigeria
Shares valued at $74,308.56 are proposed for sale by Kura Oncology (KURA) officer Kathleen Ford. - Stock Titan
Shares valued at $49,571 are in a proposed sale by Kura Oncology (KURA) officer Thomas James Doyle. - Stock Titan
A stock award triggers a tax-covering share sale by Kura Oncology (KURA) COO Kathleen Ford. - Stock Titan
A tax-related sale leaves Kura Oncology (KURA) legal chief with 187,002 shares. - Stock Titan
Kura Oncology CSO Francis Burrows Executes Stock Option and Sells Shares in September 2026 - Kalkine Media
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
After exercising options, Kura Oncology (KURA) science chief sold 20,726 shares to cover estimated payroll taxes. - Stock Titan
Form 144 KURA ONCOLOGY For: 25 September By Investing.com - Investing.com South Africa
Shares from a stock option exercise are proposed for sale by a Kura Oncology (KURA) officer, valued at $224,514. - Stock Titan
Why (KURA) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Kura Oncology stock holds at USD 11.73 as Caspian launches - AD HOC NEWS
Kura Oncology, Inc. (KURA) Stock Analysis: A Biotech Innovator with a 173% Potential Upside - DirectorsTalk Interviews
Kura Oncology to present at three investor conferences in September - scanx.trade
Kura Oncology Q2 2026 Earnings Call Transcript - Benzinga
Kura Oncology at Morgan Stanley conference: early sales, bigger bets By Investing.com - Investing.com Nigeria
Kura Oncology at Morgan Stanley conference: early sales, bigger bets - Investing.com
Kura Oncology (KURA) awards CFO 450,000 stock options - Stock Titan
Kura Oncology (KURA) CFO files initial ownership report with no trades - Stock Titan
Kura Oncology Maintains 49.2% Stake in Caspian Therapeutics Following $50M Series A Funding - Kalkine Media
symbol__ Stock Quote Price and Forecast - CNN
Kura Spins Out Caspian With $50m To Test Menin Inhibition In Diabetes - insights.citeline.com
Kura assets flow to Caspian for cardiometabolic indications - BioWorld News
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - AOL.com
Kura Oncology Raises $50M for Cardiometabolic Subsidiary Caspian - minichart.com.sg
KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil - GuruFocus
Kura Oncology at cantor conference: rapid launch, wider ambitions - Investing.com India
Kura Oncology at cantor conference: rapid launch, wider ambitions By Investing.com - Investing.com Canada
Kura Oncology, Inc. Enters into Contribution and License and Intercompany Services Agreement with Caspian Therapeutics, Inc - marketscreener.com
Kura Oncology Launches Caspian Therapeutics With $50 Million Funding - marketscreener.com
Kura Oncology Appoints Jennifer Fulk as New CFO - The Globe and Mail
Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus - TipRanks
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes - The Manila Times
Eli Lilly is among investors in a new diabetes company with $50 million - Stock Titan
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth - TradingView
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth by 2028 - TradingView
Kura Oncology at Wells Fargo conference: launch gains and pipeline breadth - investing.com
Kura Oncology Names Jennifer Fulk as Chief Financial Officer Effective September 8, 2026 - Kalkine Media
Kura Oncology Names Jennifer Fulk Chief Financial Officer - Minichart
Kura Oncology, Inc. Announces Chief Financial Officer Changes, Effective September 8, 2026 - marketscreener.com
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):